Analysis shows no extra risks in infliximab for Crohn's

10/15/2008 | MedPage Today (free registration)

An analysis of the 6,273-patient Crohn's Therapy Resource, Evaluation and Assessment Tool, or TREAT, registry found taking infliximab is not any riskier for Crohn's patients than other immunomodulating drugs. The researchers did find the risk of death increased by 86% among prednisone users and doubled for patients given narcotic analgesics.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD